Skip to Main Content

Paper Details

Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer.
Br J Cancer
2
2022
Author NameAffiliation
David W HedleyPrincess Margaret Cancer Centre, University of Toronto
  • 1 - 1

Datasets

Release 1.2